P3 Health Partners stock gained 1.44 percent on October 2
Published on 10/04/2026 at 16:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
P3 Health Partners (ISIN US7444132044) was last at USD 6.36 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, up 1.44 percent. The company agreed to issue up to USD 70 million of preferred stock and warrants under an agreement dated September 8, 2026, according to the SEC filing.
Financing adds USD 70 million
The financing consists of Series D-1 cumulative preferred stock carrying a 19.5 percent dividend rate and warrants for Class A common stock, as described in the filing dated September 11, 2026. The preferred securities are not convertible and rank ahead of the common stock for dividends and liquidation distributions, which gives the transaction a clear capital-support benefit but also adds a high-cost senior security.
The warrants carry a seven-year term and an exercise price tied to the Nasdaq minimum price on the relevant issuance date, according to the SEC filing. The structure therefore combines immediate funding with potential future dilution.
Q2 revenue reaches USD 386.38 million
P3 Health Partners reported Q2 2026 revenue of USD 386.38 million, up 11.91 percent from the comparable period, while net income reached USD 7.44 million, according to CNN. Reported earnings per share was negative USD 0.63 against consensus of negative USD 1.90, a difference of USD 1.27 per share.
The earnings mix matters because the revenue increase came alongside positive quarterly net income, while the company is still using preferred financing to strengthen its capital position. For investors, the next test is whether operating earnings can support the growth story after the financing terms and warrant dilution are included.
Two analysts see USD 18 target
A consensus tracked by Bullstory on September 18, 2026, rated P3 Health Partners Buy across 2 analysts. The average target was USD 18.00, with a low of USD 13.00 and a high of USD 23.00; the average target lies 183.0 percent above the October 2 reference price of USD 6.36.
The stock's market profile remains volatile: its 52-week range was USD 1.52 to USD 16.89 as of October 2, 2026. The distance between the latest price and the yearly high leaves financing execution, earnings quality and future share issuance as key valuation variables.
Next earnings date is November 17
P3 Health Partners stock was last at USD 6.36 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, with a daily change of 1.44 percent. The company is scheduled to report its next earnings on November 17, 2026, according to CNN.
P3 Health Partners stock at a glance
- Company: P3 Health Partners Inc.
- ISIN: US7444132044
- WKN: A412JQ
- Ticker: PIII
- Trading venue: Nasdaq
- Price (as of October 2, 2026, 4:00 p.m. ET): USD 6.36
- Market capitalization: USD 20.8 million (as of October 2, 2026)
- 52-week range: USD 1.52-16.89 (as of October 2, 2026)
- Sector / Industry: Healthcare / population health management
